UK court slaps down HGS patent

Human Genome Sciences--and other biotechs that made claims to parts of the human genetic sequence--have been dealt a blow by the U.K. The High Court yesterday ruled on the first case to question the patentability of discoveries made through the use of bioinformatics. Back in the 1990s, as scientists came to better understand the human genome, biotech companies rushed to patent genes, proteins and human cells for future research work. HGS grabbed one such patent on a disease-linked protein known as neutrokine-alpha. But now the High Court has revoked that patent, saying that "the company had failed to identify any practical use at the time its application had been filed," according to the Financial Times.

That's bad news for HGS, which is working with GlaxoSmithKline to develop a neutrokine-alpha antibody drug called lymphostat. It's a boon for Eli Lilly, however, which is developing its own neutrokine-alpha antibody drug.

- read the Financial Times summary

Related Artices:
Standards on biotech patents get tougher
GSK sues over new patent rules
Officials toss Genentech antibody patent
Universities, public institutes lead biotech revolution

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.